All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
During the AML Hub Steering Committee meeting, held in November 2023, key opinion leaders met to discuss postremission therapy for patients not proceeding to hematopoietic stem cell transplantation. This recorded session was chaired by Gail Roboz and featured Charles Craddock, Gert Ossenkoppele, Gunnar Juliusson, Jefferey Lancet, Jorge Sierra, Roland Walter, and Yasushi Miyazaki.
Post-remission therapy for patients not proceeding to HSCT
The steering committee discussed current induction strategies, how to optimize remission rates, and the impact of measurable residual disease on treatment decisions. They also considered how various global centers manage patients with NPM1-mutated acute myeloid leukemia in first morphological measurable residual disease-negative remission by polymerase chain reaction who are eligible for transplantation.
What has ASH 2020 taught us about advancing frontline chemotherapy in AML?
Increased understanding of the driving genetic and epigenetic factors of acute myeloid leukemia (AML) in recent years has helped to refine novel chemotherapy combinations in...
The passing of Professor Francesco Lo Coco: the great pioneer of targeted therapy leaves the leukemia community
Professor Francesco Lo Coco passed away on March 3, 2019.
Subscribe to get the best content related to AML delivered to your inbox